Notizie Newsletter
National Survey Reveals One in Five Young Adults Regularly Uses E-Cigarettes and Believes They are Harmless, Not Addictive
Sep 24, 2019 - Roughly one in five young adults uses e-cigarettes daily or recreationally, and nearly one in four believes the products are harmless and not addictive, according to findings from the American Society of Clinical Oncology (ASCO)’s third annual National ...Leggi tutto
Gilteritinib Approaches EU Approval for FLT3-Mutant AML
Sep 20, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of gilteritinib as a single agent for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) who have FLT3 mutations. The ...Leggi tutto
AACR Cancer Progress Report 2019 Released
Sep 18, 2019 - Today, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2019, which highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring improvements in public health ...Leggi tutto
Cancer Survival, Incidence, and Mortality in Seven High-Income Countries From 1995–2014
Sep 19, 2019 - As reported by Arnold and colleagues in The Lancet Oncology, the International Cancer Benchmarking Partnership Cancer Survival in High-Income Countries (SURVMARK-2) project has found general improvement in cancer survival between 1995 and 2014 in Australia, ...Leggi tutto
FDA Grants Enfortumab Vedotin Priority Review for Urothelial Cancer
Sep 16, 2019 - The FDA has granted a priority review designation to a biologics license application (BLA) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor ...Leggi tutto
FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
Sep 18, 2019 - The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. The approval is based on findings from the phase III TITAN trial (NCT02489318), which showed that apalutamide plus androgen deprivation therapy ...Leggi tutto